Key clinical point: VP-102 is an effective treatment for molluscum contagiosum.
Major finding: In two studies, 46% and 54% of actively treated patients had complete resolution, compared with 13% and 18% of controls, respectively.
Study details: Two phase 3, randomized, double-blind, placebo-controlled trials of 528 patients with molluscum contagiosum.
Disclosures: Verrica Pharmaceuticals sponsored the study. Dr. Eichenfield reported receiving no funding from the company; several other investigators are employees of Verrica Pharmaceuticals.
Eichenfield L et al. AAD 19, Abstract 11251.
Must Reads in Infectious Diseases
Hospital Readmission for Cellulitis Common, Costly, JAMA Dermatology; ePub 2019 Feb 27; Fisher, et al
Pneumocystosis from Exposure to Immunosuppressants, J Am Acad Dermatol; ePub 2019 Jan 9; Rekhtman, et al
FDA Approves Nuzyra for Acute Skin Infections, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
ALT-70 Gets High Marks for Diagnosing Cellulitis, J Am Acad Dermatol; ePub 2018 Jul 9; Li, et al